Answer
The safety and efficacy of CARVYKTI (ciltacabtagene autoleucel) have not been established in children under 18 years, and no data are available.
Sources for this answer
- CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.2 Posology and method of administration · Version 6Document updated
Sources checked